Contact us: +91 9550333722 040 - 40102781
Structured search
India
Choose your country
Different countries will display different contents
Try our best to find the right business for you.
My chemicalbook

Welcome back!

HomeProduct name listRabacfosadine succinate

Rabacfosadine succinate

Rabacfosadine succinate Structural

What is Rabacfosadine succinate?

Description

Rabacfosadine succinate, also known as VDC-1101 or GS-9219, is a double prodrug of the nucleotide analogue 9-(2-phosphonylmethoxyethl)guanine (PMEG). It is a novel chemotherapy drug approved for the treatment of lymphoma in dogs. Rabacfosadine administered every 3 weeks is usually well tolerated and has shown significant anti-tumour activity in dogs with previously untreated medium and large cell lymphoma.

The Uses of Rabacfosadine succinate

Rabacfosadine succinate is used as the acyclic nucleoside phosphonate PMEG double prodrug.

Mechanism of action

Rabacfosadine succinate targets lymphocytes and acts as an anti-tumour agent by inhibiting DNA synthesis through the inhibition of DNA polymerase.

Side Effects

The most common adverse reaction to Rabacfosadine succinate is gastrointestinal (anorexia/diarrhoea), which is generally resolved by supportive therapy and/or dose adjustment. Three dogs developed VCOG-CTCAE grade 5 delayed pulmonary fibrosis.

Properties of Rabacfosadine succinate

Safety information for Rabacfosadine succinate

Computed Descriptors for Rabacfosadine succinate

InChIKey XLBDQSJWTNREFA-FGVWXQOBNA-N
SMILES C(C(=O)O)CC(=O)O.C(N1C=NC2=C(N=C(N)N=C12)NC1CC1)COCP(=O)(N[C@@H](C)C(=O)OCC)N[C@@H](C)C(=O)OCC |&1:29,37,r|

You may like

Statement: All products displayed on this website are only used for non medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.